Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Collaborator: Mansoura University
• Treatments: Biguanides; Empagliflozin; Metformin

Criteria

Inclusion Criteria:

• Patients with mild or/and moderate chronic kidney disease (stages 2 or/and 3, estimated glomerular filtration rate (eGFR) between 30-89 ml/min/1.73 m2) at the time of the baseline visit.

• Patients with and without type 2 diabetes.

• Patients with or without proteinuria.

• Age: ≥ 18 years.

Exclusion Criteria:

• Type 1 diabetes.

• Patients with eGFR ˂30 ml/min/1.73 m2.

• Patients with known hepatic cell failure.

• Decompensated heart requiring acute management.

• Active malignancy.

• Planned coronary or surgical interventions.

• Known hypersensitivity to study medications.

• Chronic inflammation, trauma, or infection.

• Pregnant or lactating women.

• Patients already on metformin or a sodium-glucose cotransporter-2 (SGLT2) inhibitor.

• Any of the study treatments labeled contraindications.